{"product_id":"3sbio-bcg-matrix","title":"3SBio Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUncover the strategic positioning of 3SBio's product portfolio with our insightful BCG Matrix preview. See how their offerings stack up as Stars, Cash Cows, Dogs, or Question Marks, and understand the foundational insights into their market performance.\u003c\/p\u003e\n\u003cp\u003eReady to transform this snapshot into actionable strategy? Purchase the full BCG Matrix report for a comprehensive, quadrant-by-quadrant breakdown, complete with data-driven recommendations and a clear roadmap for optimizing 3SBio's investments and product development. Gain the competitive edge you need.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSSGJ-707 (PD-1\/VEGF Bispecific Antibody)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSSGJ-707, a bispecific antibody targeting PD-1 and VEGF, is a prime candidate for 3SBio's future growth. Developed on their CLF2 platform, this therapy holds substantial promise.  Pfizer's recent acquisition of global rights outside of China, including a $1.25 billion upfront payment and potential milestones up to $4.8 billion, underscores the immense market confidence and projected revenue potential.\u003c\/p\u003e\n\u003cp\u003eThis strategic partnership with Pfizer highlights SSGJ-707's position as a significant future revenue stream for 3SBio. The drug is currently undergoing clinical trials in China for several cancer types, such as non-small cell lung cancer and metastatic colorectal cancer. These ongoing trials are crucial for validating its efficacy and paving the way for broader market access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAnti-IL-17A mAb (608)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe anti-IL-17A mAb (608) is positioned as a potential Star within the 3SBio BCG Matrix. Its Phase III trial for plaque psoriasis concluded successfully in 2024, meeting all primary efficacy goals. This strong clinical performance, coupled with the submission and acceptance of its New Drug Application by the NMPA, signals significant market potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-acting Erythropoietin (SSS06)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLong-acting Erythropoietin (SSS06) represents a promising development for 3SBio, fitting the profile of a potential star product. Its submission for a new drug application in 2024 highlights its innovative nature within the established erythropoiesis-stimulating agent (ESA) market. This long-acting formulation aims to enhance patient convenience and adherence, targeting a growing segment in nephrology and anemia management.\u003c\/p\u003e\n\u003cp\u003eThe global anemia treatment market was valued at approximately USD 35 billion in 2023 and is projected to grow at a CAGR of around 5% through 2030, driven by increasing prevalence of chronic kidney disease and cancer. SSS06's potential to capture a significant share of this expanding market, building on 3SBio's existing rhEPO market leadership, strongly supports its classification as a star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClifutinib \/ HER2-targeting ADC DB-1303\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e3SBio is strategically expanding its oncology portfolio by securing commercialization rights for Clifutinib from HEC and the HER2-targeting ADC DB-1303 from Duality Biologics. These moves are designed to bolster their presence in the oncology market.\u003c\/p\u003e\n\u003cp\u003eBoth Clifutinib and DB-1303 are currently in Phase III clinical trials, with expected New Drug Application (NDA) submissions projected for 2026 and 2027, respectively. This timeline positions these assets as key future revenue drivers.\u003c\/p\u003e\n\u003cp\u003eThese in-licensing deals are crucial for 3SBio's growth, reflecting a deliberate effort to build a robust and competitive oncology pipeline. The company aims to differentiate itself in this rapidly evolving therapeutic area.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eClifutinib (HEC):\u003c\/strong\u003e Phase III, anticipated 2026E NDA submission.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDB-1303 (Duality Biologics):\u003c\/strong\u003e HER2-targeting ADC, Phase III, anticipated 2027E NDA submission.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Importance:\u003c\/strong\u003e Enhances 3SBio's oncology pipeline and market position.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGrowth Opportunity:\u003c\/strong\u003e Both products represent significant potential for future revenue generation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAnti-IL-1β mAb (613)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe anti-IL-1β mAb (613) is a promising candidate in 3SBio's pipeline, currently in Phase III trials for acute gouty arthritis. Patient enrollment for these trials was successfully completed in 2024, marking a significant milestone.\u003c\/p\u003e\n\u003cp\u003eThis therapeutic addresses a clear unmet need in the autoimmune disease sector, a market experiencing robust growth. The global autoimmune disease market was valued at approximately $110 billion in 2023 and is projected to grow at a CAGR of over 7% through 2030, indicating substantial commercial potential for effective treatments.\u003c\/p\u003e\n\u003cp\u003eSuccessful completion of its Phase III trials and subsequent regulatory approval would solidify 613's position as a key asset within 3SBio's immunology segment. This could lead to significant market penetration, especially given the limited number of targeted therapies currently available for severe gout flares.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct:\u003c\/strong\u003e Anti-IL-1β mAb (613)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIndication:\u003c\/strong\u003e Acute Gouty Arthritis\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDevelopment Stage:\u003c\/strong\u003e Phase III (Patient enrollment completed 2024)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Opportunity:\u003c\/strong\u003e Addresses unmet need in growing autoimmune disease market (valued at ~$110 billion in 2023)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e3SBio's Stars: High Growth, High Potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars in the 3SBio BCG Matrix represent products with high market share and high growth potential. These are typically innovative therapies in expanding markets, poised to become significant revenue drivers. Products like SSGJ-707, the anti-IL-17A mAb (608), and Long-acting Erythropoietin (SSS06) fit this description, showcasing strong clinical progress and market validation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eDevelopment Stage\u003c\/th\u003e\n\u003cth\u003eMarket Potential\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSSGJ-707\u003c\/td\u003e\n\u003ctd\u003eOncology (PD-1\/VEGF)\u003c\/td\u003e\n\u003ctd\u003eClinical Trials\u003c\/td\u003e\n\u003ctd\u003eHigh (Pfizer partnership, $1.25B upfront)\u003c\/td\u003e\n\u003ctd\u003eBispecific antibody, CLF2 platform\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnti-IL-17A mAb (608)\u003c\/td\u003e\n\u003ctd\u003ePlaque Psoriasis\u003c\/td\u003e\n\u003ctd\u003ePhase III Complete, NDA Submitted\u003c\/td\u003e\n\u003ctd\u003eSignificant\u003c\/td\u003e\n\u003ctd\u003eSuccessful Phase III, NMPA acceptance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-acting Erythropoietin (SSS06)\u003c\/td\u003e\n\u003ctd\u003eAnemia Management\u003c\/td\u003e\n\u003ctd\u003eNDA Submitted\u003c\/td\u003e\n\u003ctd\u003eHigh (Growing ESA market ~$35B in 2023)\u003c\/td\u003e\n\u003ctd\u003eEnhances patient convenience\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnti-IL-1β mAb (613)\u003c\/td\u003e\n\u003ctd\u003eAcute Gouty Arthritis\u003c\/td\u003e\n\u003ctd\u003ePhase III (Enrollment Complete 2024)\u003c\/td\u003e\n\u003ctd\u003eSubstantial (Autoimmune market ~$110B in 2023)\u003c\/td\u003e\n\u003ctd\u003eAddresses unmet need\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThe 3SBio BCG Matrix analyzes its product portfolio across Stars, Cash Cows, Question Marks, and Dogs, guiding strategic investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThe 3SBio BCG Matrix provides a clear, visual snapshot of your product portfolio, eliminating the pain of complex data analysis.\u003c\/p\u003e\n\u003cp\u003eGain strategic clarity by instantly categorizing products, simplifying decision-making and resource allocation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTPIAO (Recombinant Human Thrombopoietin)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTPIAO, 3SBio's leading product, is the sole commercial recombinant human thrombopoietin globally. In 2024, it achieved impressive sales of RMB 5.062 billion, marking a significant 20.4% growth compared to the previous year.\u003c\/p\u003e\n\u003cp\u003eThis drug commands a substantial market share, holding 65.0% in Mainland China for thrombocytopenia treatment in 2023 and expanding to 66.2% in the first half of 2024. Its consistent high sales and market dominance, bolstered by its presence in essential clinical guidelines and recent pediatric approval, solidify TPIAO's position as a robust cash cow for 3SBio, ensuring steady and significant cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEPIAO and SEPO (Recombinant Human Erythropoietins)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEPIAO and SEPO, 3SBio's recombinant human erythropoietins, have been market leaders for over twenty years.  As of the first half of 2024, these products collectively commanded 42.7% of the Mainland China rhEPO market. \u003c\/p\u003e\n\u003cp\u003eThese established drugs operate in a mature, low-growth market, yet their high market share translates into consistent, substantial cash flow for 3SBio. Their long-standing presence means promotional investments are minimal, further enhancing their profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYisaipu (TNF-α Inhibitor)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eYisaipu, a Tumour Necrosis Factor (TNF) α inhibitor, stands as a prime example of a cash cow within 3SBio's portfolio. As the first-to-market product of its kind in Mainland China, it commanded a significant 22.7% market share in the TNF-α inhibitor sector in 2023. This strong market position, coupled with consistent sales growth and ongoing market expansion efforts, solidifies its status as a reliable revenue generator in a well-established therapeutic area.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMandi (Minoxidil for Hair Loss)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMandi, a prominent hair loss treatment, is a classic example of a Cash Cow within the 3SBio BCG Matrix.  Its impressive sales reached RMB 1.337 billion in 2024, reflecting an 18.9% year-on-year growth. This strong performance is underpinned by its commanding 72.6% market share in the Mainland China minoxidil tincture segment as of 2023. \u003c\/p\u003e\n\u003cp\u003eThe recent introduction of Mandi's foam formulation is a strategic move that further cements its leadership in a mature market. This innovation allows Mandi to continue generating substantial profits with a relatively stable, albeit lower, growth rate, characteristic of a Cash Cow. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eSales in 2024:\u003c\/strong\u003e RMB 1.337 billion\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eYear-on-Year Sales Growth:\u003c\/strong\u003e 18.9%\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Share (2023):\u003c\/strong\u003e 72.6% in Mainland China minoxidil tincture market\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Advantage:\u003c\/strong\u003e Dominant position in a mature market, reinforced by new product formulations.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCipterbin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCipterbin demonstrates robust performance within its therapeutic area, marked by expanding clinical use and extended patient treatment durations. This has fueled significant sales expansion throughout 2024, positioning it as a key revenue generator.\u003c\/p\u003e\n\u003cp\u003eWhile precise market share figures for Cipterbin are not publicly detailed, its sustained, rapid sales trajectory in a mature market segment strongly indicates high profitability and consistent cash flow. This aligns with the characteristics of a Cash Cow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrong Sales Growth:\u003c\/strong\u003e Cipterbin experienced rapid sales growth in 2024 due to increased clinical recognition and longer treatment cycles.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHigh Profitability:\u003c\/strong\u003e The product's performance suggests it commands high profit margins, typical of a mature, successful product.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStable Cash Generation:\u003c\/strong\u003e Consistent sales in an established market point to a reliable and stable source of cash for the company.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Importance:\u003c\/strong\u003e As a Cash Cow, Cipterbin likely funds research and development for other products or business ventures.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e3SBio's Cash Cows: Steady Revenue Streams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCash Cows in the 3SBio portfolio represent products with high market share in mature, low-growth industries. These products generate substantial and consistent cash flow, often requiring minimal investment for maintenance.\u003c\/p\u003e\n\u003cp\u003eThey are crucial for funding other business activities, such as research and development for new products or supporting Stars and Question Marks.\u003c\/p\u003e\n\u003cp\u003eTPIAO, EPIAO, SEPO, Yisaipu, Mandi, and Cipterbin all exhibit characteristics of Cash Cows due to their strong market positions and consistent revenue generation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct\u003c\/td\u003e\n\u003ctd\u003e2024 Sales (RMB billions)\u003c\/td\u003e\n\u003ctd\u003eYoY Growth\u003c\/td\u003e\n\u003ctd\u003eMarket Share (approx.)\u003c\/td\u003e\n\u003ctd\u003eCategory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTPIAO\u003c\/td\u003e\n\u003ctd\u003e5.062\u003c\/td\u003e\n\u003ctd\u003e20.4%\u003c\/td\u003e\n\u003ctd\u003e66.2% (China rhEPO)\u003c\/td\u003e\n\u003ctd\u003eBiopharmaceutical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEPIAO \u0026amp; SEPO (combined)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e42.7% (China rhEPO)\u003c\/td\u003e\n\u003ctd\u003eBiopharmaceutical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYisaipu\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e22.7% (China TNF-α inhibitor)\u003c\/td\u003e\n\u003ctd\u003eBiopharmaceutical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMandi\u003c\/td\u003e\n\u003ctd\u003e1.337\u003c\/td\u003e\n\u003ctd\u003e18.9%\u003c\/td\u003e\n\u003ctd\u003e72.6% (China minoxidil tincture)\u003c\/td\u003e\n\u003ctd\u003eConsumer Health\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCipterbin\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eStrong Growth\u003c\/td\u003e\n\u003ctd\u003eUndisclosed\u003c\/td\u003e\n\u003ctd\u003eBiopharmaceutical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e3SBio BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe 3SBio BCG Matrix preview you are viewing is the identical, fully formatted document you will receive immediately after purchase. This means no watermarks, no demo content, and no surprises – just the complete, analysis-ready BCG Matrix report ready for your strategic planning needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55610799948153,"sku":"3sbio-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/3sbio-bcg-matrix.png?v=1754746427","url":"https:\/\/growthsharematrix.com\/products\/3sbio-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}